USSTOCK.TODAY
After-Market
Log in Sign up

Amgen confirms 58% reduction in lung cancer death risk with Imdeltratra and Imfinzi combination therapy

The Motley Fool +1 · ·by G4L

AMGN AMGEN Inc
$465.09 +1.01%
View chart & analysis →
  1. 1Combining Amgen's Imdeltratra with Imfinzi reduced the risk of death in patients with extensive-stage small cell lung cancer by 58%.
  2. 2Imdeltratra recorded a growth rate of 115% through the first half of 2026.
  3. 3Amgen recorded 22 products with double-digit revenue growth in the second quarter.

So what's the key point?

Using Amgen's drug together with another drug reduced the risk of death for lung cancer patients by 58%. This drug is growing rapidly and is driving up Amgen's revenue.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Amgen shares fall on biosimilar concerns despite third-quarter earnings beat Investing.com +1 · 5d agoAmgen's Imdeltratra Reduces Death Risk in Extensive-Stage Small Cell Lung Cancer by 58% CNBC · Oct 24Amgen and AstraZeneca Announce Phase 3 Clinical Trial Results for Tezspire in Eosinophilic Esophagitis Nasdaq +1 · Oct 21
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news